Hospital admissions for blood in the urine
Official title: Ward AdmiSsion of Haematuria: an Observational mUlticentre sTudy
Run by British Urology Researchers in Surgical Training · NCT07395037 · Data updated 2026-11-12
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1050 (estimated) |
| Sponsor | British Urology Researchers in Surgical Training Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | April 30, 2026 |
| Study ends | April 30, 2026 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT07395037 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 16 or older who are admitted urgently to a participating urology service with haematuria (not immediately after documented catheter-related urethral trauma) and who remain in hospital for at least 24 hours.
✕Probably not a fit
Children under 16, patients with immediate catheter-related urethral trauma, and those discharged within 24 hours are excluded and are unlikely to benefit directly from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The WASHOUT project is an international, multicentre prospective observational study describing how adults admitted emergently with haematuria are managed across participating hospitals. Using the BURST collaborative model, sites collect standardized data on demographics, comorbidities, investigations, interventions and clinical outcomes with a common case report form. Primary outcome is hospital length of stay and secondary outcomes include time to diagnosis, 90-day mortality, readmission rates and healthcare resource use; analyses will use multilevel regression to explore practice variation and outcome drivers. Patients and the public were involved in the design to ensure the outcomes reflect patient priorities and real-world concerns.
Why it matters
Potential benefit: If successful, this work could produce consensus guidance that shortens hospital stays, reduces complications and makes urgent haematuria care more consistent across hospitals.
How similar studies have gone: There have been single-center and regional audits that informed local practice, but few large international prospective observational efforts like this to comprehensively compare emergency haematuria management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are included if they are over 16 years of age or older and admitted to a participating urological secondary care centre * admitted as an emergency with haematuria as the primary or secondary diagnosis under the primary or joint care of urology Exclusion Criteria: * any patients under 16 years of age * patients with catheter-related urethral trauma (defined as haemturia immediately after insertion of a urethral catheter that was documented as traumatic by the clinician, with no previous history of haemturia prior to catheter insertion) * patients that are in hospital less than 24 hours.
Where it's running
-
Burst
London, United Kingdom Recruiting
Study contacts
- Study coordinator: Kevin Byrnes, PhD
- Email: byrneskg@gmail.com
- Phone: 020 7679 2000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do women over 50 with sudden bladder infection symptoms and visible blood in their urine need full cancer checks?
This project will see if women 50 and older who have sudden visible blood in their urine with short-term bladder infection symptoms can safely avoid full cancer investigations.
-
Mobile health outreach for men's cancer screening
This study is testing a mobile health service that brings cancer screening directly to men at their workplaces, especially those in high-risk groups, to help them get checked for prostate cancer and other urological issues.
-
Reducing invasive tests for patients with blood in urine
This study is testing a new urine test to see if it can help people with blood in their urine avoid unnecessary invasive procedures while still checking for serious conditions like bladder cancer.
-
Screening for bladder cancer using urine tests
This study is testing if regular urine tests every six months can help catch bladder cancer earlier in people over 50 who are at high risk.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.